title: Hematologic toxicity and double autografting of stem cells after myeloablative activities of yttrium-90-ibritumomab tiuxetan.
authors.forename: Anna
authors.initials: A
authors.lastname: Vanazzi
authors.forename: Marta
authors.initials: M
authors.lastname: Cremonesi
authors.forename: Giovanni
authors.initials: G
authors.lastname: Paganelli
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000191:economics; D033581:Stem Cell Transplantation / Q000191:economics / Q000379:methods*; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000191:economics
chemical_list: D000911:Antibodies, Monoclonal; C422802:ibritumomab tiuxetan